Other
Amgen·Balance Sheet Statement·32 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Identifiable Intangible Assets Gross | $56.2B | $56.2B | $56.1B | $55.3B | $55.4B | $55B | $55.1B | $55B |
| Gross Carrying Amount | $55.1B | $55.1B | $55.1B | $54.3B | $54.7B | $54.3B | $54.4B | $54.3B |
| Finite-Lived Intangible Assets, Accumulated Amortization | $26B | $27.3B | $28.4B | $29.6B | $30.8B | $31.9B | $32.8B | $33.7B |
| Identifiable Intangible Assets Accumulated Amortization | $26B | $27.3B | $28.4B | $29.6B | $30.8B | $31.9B | $32.8B | $33.7B |
| Cumulative Cost Basis | $8.8B | $8.6B | $11.5B | $8.3B | $7.5B | $8.7B | $8.5B | $11.5B |
| Total | $8.8B | $8.6B | $11.5B | $8.3B | $7.5B | $8.7B | $8.5B | $11.5B |
| Available for sale investments | $8.8B | $8.6B | $11.5B | $8.3B | $7.5B | $8.7B | $8.5B | $11.5B |
| Share Repurchase Program, Remaining Authorized, Amount | $7B | $7B | — | $6.8B | $6.8B | $6.8B | — | $6.8B |
| Debt issuances | — | — | — | — | — | — | — | $4B |
| Syndicated, unsecured revolving credit facility capacity | — | — | — | — | — | — | — | $4B |
| 2027 | $4.5B | $4.5B | — | $3.7B | $3.7B | $3.6B | — | $3.6B |
| 2028 | $3.9B | $3.9B | — | $3.7B | $3.7B | $3.5B | — | $2.8B |
| Common stock, shares authorized (in shares) | $2.8B | $2.8B | $2.8B | $2.8B | $2.8B | $2.8B | $2.8B | $2.8B |
| Remainder of 2026 | $2.4B | $1.2B | — | $3.1B | $2B | $900M | — | $2.7B |
| Remainder of Fiscal Year 2024 | $2.4B | $1.2B | — | $3.1B | $2B | $900M | — | $2.7B |
| Remainder of Fiscal Year 2025 | $2.4B | $1.2B | — | $3.1B | $2B | $900M | — | $2.7B |
| 2029 | $3.9B | $3.9B | — | $2.8B | $2.9B | $2.8B | — | $2.3B |
| 2030 | $2.9B | $2.9B | — | $2.2B | $2.3B | $2.3B | — | $2.2B |
| 2031 | $2.2B | $2.2B | — | $2.1B | $2.2B | $2.2B | — | $2.1B |
| Deferred income taxes | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.5B | $1.4B | $1.3B |
| Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $1.4B | $1.4B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B |
| Fair Value Measurement Disclosure | $1B | $886M | $1B | $880M | $1B | $904M | $827M | $792M |
| Gross Assets/Liabilities | $1B | $886M | $1B | $880M | $1B | $904M | $827M | $792M |
| Derivatives, gross, liabilities | $1B | $886M | $1B | $880M | $1B | $904M | $827M | $792M |
| Common Stock, Shares, Outstanding | $537.2M | $537.5M | $536.9M | $537.7M | $538.3M | $538.5M | $538.8M | $539.7M |
| Derivative, gross, assets | $270M | $112M | $420M | $195M | $109M | $142M | $244M | $249M |
| Business Combination, Contingent Consideration, Liability | $107M | $112M | $106M | $104M | $90M | $95M | $161M | $173M |
| Other (including finance leases) | $29M | $27M | $24M | $28M | $26M | $24M | $27M | $25M |
| Common stock, par value (in dollars per share) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Unrealized Gains | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Amount outstanding under the credit facility | — | — | — | — | — | — | $0 | $0 |